Clinical Rheumatology

, Volume 9, Issue 4, pp 461–474 | Cite as

A three year comparative study of auranofin and gold sodium thiomalate in rheumatoid arthritis

  • R. Rau
  • M. Schattenkirchner
  • H. Muller-Fassbender
  • B. Kaik
  • H. Zeidler
  • B. Missler
Originals

Summary

One hundred twenty-one patients with active RA were randomly assigned to receive 6 mg auranofin (AF)/day (60 patients) or 50 mg gold sodium thiomamate (GST)/week (62 patients) in a double-blind fashion. There were no intergroup differences with respect to sex, age, duration (median 2 years), stage and activity of the disease. In the case of “striking improvement” after 24 weeks a dose reduction to 50 mg GST/month or 4 mg AF/day was allowed and carried out in all GST patients and no AF patient. The serum gold levels were 5 times higher with weekly GST, they approached those of the AF group with monthly GST injections. The clinical parameters — number of swollen joints, activity index, articular index, grip strength, ESR — improved significantly in both groups, but grip strength, articular index and ESR improved more pronounced in the GST group. The X-ray progression (hands and forefeet) was significantly greater in the AF group. Fourthy eight AF patients (80%) and 39 GST patients (36%) completed the first year. Thereafter the study was continued as an open study but the patients were allowed to switch from GST to AF. After the first and second year 14/7 GST patients switched to AF. The second/third year was completed by 37/22 AF pat. (62%/37%) and by 15/8 GST pat. (24%/13%). Skin reactions were more common with GST (41.9%/26.7%), diarrhoea was more common with AF (36.7%/19.4%), proteinuria occurred in 10% in both groups, leucopenia and thrombocytopenia were rare in both groups (1.7%). The withdrawal rate due to adverse events was 10%/26% in the AF/GST group during the first year (p<0.05) and 25%/32% over the three year period (n.s.).

Conclusion

Both AF and GST are effective in the long-term treatment of RA, but GST is more so in radiological progression and ESR.

Key words

Auranofin Gold Sodium Thiomalate Rheumatoid Arthritis Treatment Long-term Treatment Gold Salts 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Berglof, F.E., Berglof, K., Walz, D.T. Auranofin: an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. J Rheumatol 1978, 5, 68–74.PubMedGoogle Scholar
  2. 2.
    Katz, W.A., Alexander, S., Bland, J.H., Blechmann, W., Bluhm, G.B., Bonebrake, R.A. et al. The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis. J Rheumatol (suppl) 1982, 9, 173–178.Google Scholar
  3. 3.
    Schattenkirchner, M., Kaik, B., Müller-Fassbender, H., Rau, R., Zeidler, H. Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis: a double-blind comparative multicenter study. J Rheumatol (suppl) 1982, 9, 184–189.Google Scholar
  4. 4.
    Rau, R., Kaik, B., Müller-Fassbender, H., Schattenkirchner, M., Zeidler, H. Auranofin (SK&F 39162) and sodium aurothiomalate in the treatment of rheumatoid arthritis. A double-blind comparative multicenter study. Proceedings of an International Gold Workshop, Munich 1982. In: Modern Aspects of Gold Therapy. Ed: M. Schattenkirchner, W. Müller, Karger, Basel 1983, pp. 162–174.Google Scholar
  5. 5.
    Kaik, B., Broil, H., Müller-Fassbender, H., Rau, R., Schattenkirchner, M., Zeidler, H. Auranofin and Tauredon in the treatment of chronic polyarthritis. Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam, 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris, New York, Excerpta Medica, 1983, pp. 453–463.Google Scholar
  6. 6.
    Schattenkirchner, M., Bröll, H., Kaik, B., Müller-Fassbender, H., Rau, R., Zeidler, H. Auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis: a one-year double-blind comparative multicenter study. Klin Wochenschr 1988, 66, 167–174.PubMedGoogle Scholar
  7. 7.
    Ropes, M.W., Bennett, G.A., Cobb, S. et al. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958, 9, 175–176.PubMedGoogle Scholar
  8. 8.
    Steinbrocker, O., Traegger, Ch., Batterman, R.C. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949, 140, 659–662.Google Scholar
  9. 9.
    Lansbury, J. Methods for evaluating rheumatoid arthritis. Eds: Hollander, J.L., McCarty, D.J. In: Arthritis and Allied Conditions, 8th ed., Philadelphia, Lea & Febinger, 1972, pp. 419–437.Google Scholar
  10. 10.
    Larsen, A., Dale, K., Eek, M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977, 18, 481.Google Scholar
  11. 11.
    Chalkins, E. Semi-quantitative criteria for estimating degrees of disease activity of rheumatoid arthritis. Committee Report to Am Rheum Assoc, 1962.Google Scholar
  12. 12.
    Larsen, A., Horton, J., Osborne, C. Auranofin compared with intramuscular gold in the long-term treatment of rheumatoid arthritis: an X-ray analysis. Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York, Excerpta Medica, 1983, pp. 264–274.Google Scholar
  13. 13.
    Van Riel, P.L.C.M., van de Putte, B.A., Gribnau, F.W.J., Macrae, K.D., de Rooy, D.J.A.M. A single-blind comparative study of auranofin and gold thioglucose in patients with rheumatoid arthritis. Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York, Excerpta Medica, 1983, pp. 135–145.Google Scholar
  14. 14.
    Dequeker, J., Francx, L., Deckers, Y. Comparison of oral gold (auranofin) and injectable gold (allochrysine, gold sodium thiopropanolsulphonate) treatment in patients with rheumatoid arthritis: a single-blind study. Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York, Excerpta Medica, 1983, pp. 156–163.Google Scholar
  15. 15.
    Kahn, M.F., Doury, P., Delcambre, B., Desproges-Gotteron, R., Gougeon, J., Kuntz, D., D. Eshougues, J.R., Roux, H., Sany, J. A multicentre double-blind comparative study of auranofin and intramuscular gold (allochrysine). Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York, Excerpta Medica, 1983, pp. 165–178.Google Scholar
  16. 16.
    Davies, J., Bacon, P.A., Hall, N.D., Ring, E.F.J. Placebo-controlled comparison of auranofin with myocrisin in patients with rheumatoid arthritis. Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York, Excerpta Medica, 1983, pp. 194–200.Google Scholar
  17. 17.
    Barraclough, D., Boyden, K., Brooks, P., Thomas, D., Tymms, K. A comparative study of auranofin, gold sodium thiomalate and D-penicillamine in rheumatoid arthritis: a progress report. Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York, Excerpta Medica, 1983, pp. 240–245.Google Scholar
  18. 18.
    Davis, P., Menard, H., Thompson, J., Harth, M., Beaudet, F. One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis. Rheumatology 1985, 12, 1, 60–67.Google Scholar
  19. 19.
    Capell, H.A., Lewis, D., Carey, J. A three-year follow-up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis. Ann Rheum Dis 1986, 45, 705–711.PubMedGoogle Scholar
  20. 20.
    Harth, M., Davis, P., Thompson, J.M., Menard, H., Beaudet, F. Comparison between sodium aurothiomalate and auranofin in rheumatoid arthritis. Results of a two-year open randomized study. Scand J Rheumatol 1987, 16, 177–184.PubMedGoogle Scholar
  21. 21.
    Ward, J.R., Williams, H.J., Egger, M.J. et al. Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of active rheumatoid arthritis: response by treatment duration. Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam, 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York. Excepta Medica, 1983, pp. 115–132.Google Scholar
  22. 22.
    Lewis, D., Capell, H.A. Is auranofin preferable to gold sodium thiomalate in the management of rheumatoid arthritis? Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam, 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York. Excerpta Medica, 1983, pp. 147–154.Google Scholar
  23. 23.
    Ward, J.R., Williams, H.J., Boyce, E., Egger, M.J., Reading, J.C., Samuelson jr. C.O. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Am J Med 1983, 12, 133–137.Google Scholar
  24. 24.
    Smith, P.R., Brown, G.M.M., Meyers, O.L. A 96-week open comparative study of auranofin versus gold sodium thiomalate in rheumatoid arthritis. Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam, 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York, Excerpta Medica, 1983, pp. 181–191.Google Scholar
  25. 25.
    Wenger, M.E., Bernhard, G.C., Heller, M.D. et al. Therapy for rheumatoid arthritis: transferring treatment from injectable gold to auranofin. Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York, Excerpta Medica, 1983, pp. 201–208.Google Scholar
  26. 26.
    Berry, H., Crisp, A.J., Coughlan, R.J. et al. Double-blind comparison of auranofin and myocrisin. Auranofin: Proceedings of Smith, Kline & French International Symposium, Amsterdam, 1982. Eds: H.A. Capell, D.S. Cole, K.F. Mangham, R.W. Morris. New York, Excerpta Medica, 1983, pp. 211–225.Google Scholar
  27. 27.
    Lorber, A. Monitoring gold plasma levels in rheumatoid arthritis. Clin Pharmacokinet 1977, 2, 127.PubMedGoogle Scholar
  28. 28.
    Cats, A. Multicentre controlled trial of the effects of different dosage of gold therapy, followed by maintenance dosage. Agent Actions 1976, 6, 355.Google Scholar
  29. 29.
    Ellman, P., Lawrence, J.S., Thorhold, G.P.T. Gold therapy in rheumatoid arthritis. Br Med J 1940, 2, 312.Google Scholar
  30. 30.
    Larsen, A., Horton, J., Howland, C. The effects of auranofin and parenteral gold in the treatment of rheumatoid arthritis; an X-ray analysis. Clin Rheumatol 1984, 3 (Suppl 1), 97–104.PubMedGoogle Scholar
  31. 31.
    Van Riel, P.L.C.M., Larsen, A., van de Putte, L.B.A., Gribnau, F.W.J. Effects of aurothioglucose and auranofin on radiographic progression in rheumatoid arthritis. Clin Rheumatol 1986, 5, 3, 359–364.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • R. Rau
    • 1
  • M. Schattenkirchner
    • 1
    • 2
  • H. Muller-Fassbender
    • 1
    • 3
  • B. Kaik
    • 1
    • 4
  • H. Zeidler
    • 1
    • 5
  • B. Missler
    • 1
    • 6
  1. 1.Rheumaklinik, Evangelisches FachkrankenhausRatingen 1Germany
  2. 2.Medizinische PoliklinikMünchenGermany
  3. 3.RheumazentrumBad AbbachGermany
  4. 4.Kaiser Frans-Jozef SpitalWienAuxtria
  5. 5.Rheumatologische UniversitätsklinikHannoverGermany
  6. 6.Smith, Kline & FrenchMunchenGermany

Personalised recommendations